SEI Investments’s Enanta Pharmaceuticals ENTA Stock Holding History

SEI Investments’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.38M	Buy	109,077 +10,295	+10%	+$138K	﹤0.01%	2194
2025 Q4	$1.56M	Buy	98,782 +24,929	+34%	+$317K	﹤0.01%	1980
2025 Q3	$884K	Hold	73,853	–	–	﹤0.01%	2010
2025 Q2	$558K	Hold	73,853	–	–	﹤0.01%	2138
2025 Q1	$408K	Buy	73,853 +1,064	+1%	+$6.57K	﹤0.01%	2216
2024 Q4	$419K	Sell	72,789 -136	-0.2%	-$1.3K	﹤0.01%	2243
2024 Q3	$756K	Hold	72,925	–	–	﹤0.01%	2042
2024 Q2	$946K	Sell	72,925 -15,230	-17%	-$206K	﹤0.01%	1926
2024 Q1	$1.54M	Hold	88,155	–	–	﹤0.01%	1726
2023 Q4	$830K	Buy	88,155 +40,276	+84%	+$375K	﹤0.01%	1941
2023 Q3	$535K	Buy	+47,879	New	+$771K	﹤0.01%	2089
2022 Q3	–	Sell	-13,942	Closed	-$659K	–	2670
2022 Q2	$659K	Sell	13,942 -4,628	-25%	-$251K	﹤0.01%	1994
2022 Q1	$1.32M	Sell	18,570 -9,186	-33%	-$598K	﹤0.01%	1711
2021 Q4	$2.06M	Buy	27,756 +8,178	+42%	+$642K	﹤0.01%	1573
2021 Q3	$1.1M	Buy	19,578 +3	+0%	+$148	﹤0.01%	1750
2021 Q2	$841K	Sell	19,575 -242	-1%	-$11.9K	﹤0.01%	1883
2021 Q1	$943K	Sell	19,817 -148	-0.7%	-$7.38K	﹤0.01%	1777
2020 Q4	$815K	Sell	19,965 -1,010	-5%	-$44.4K	﹤0.01%	1773
2020 Q3	$937K	Buy	20,975 +1,753	+9%	+$84.9K	﹤0.01%	1629
2020 Q2	$958K	Buy	19,222 +1,844	+11%	+$95.4K	﹤0.01%	1575
2020 Q1	$894K	Sell	17,378 -3,261	-16%	-$174K	﹤0.01%	1503
2019 Q4	$1.27M	Hold	20,639	–	–	﹤0.01%	1539
2019 Q3	$1.24M	Hold	20,639	–	–	﹤0.01%	1519
2019 Q2	$1.74M	Hold	20,639	–	–	0.01%	1371
2019 Q1	$1.97M	Buy	20,639 +4,679	+29%	+$420K	0.01%	1316
2018 Q4	$1.33M	Buy	15,960 +232	+1%	+$17.8K	﹤0.01%	1443
2018 Q3	$1.32M	Buy	15,728 +13,460	+593%	+$1.35M	﹤0.01%	1386
2018 Q2	$263K	Buy	2,268 +346	+18%	+$34.5K	﹤0.01%	1975
2018 Q1	$156K	Buy	1,922 +1,919	+63,967%	+$148K	﹤0.01%	1975
2017 Q4	$0	Buy	+3	New	+$150	﹤0.01%	3372
2015 Q4	–	Sell	-10,024	Closed	-$362K	–	2559
2015 Q3	$362K	Buy	+10,024	New	+$430K	﹤0.01%	1406
2015 Q1	–	Sell	-111	Closed	-$6K	–	2270
2014 Q4	$6K	Buy	+111	New	+$4.97K	﹤0.01%	1929

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SEI Investments's ENTA Position: Q1 2026 in Review

SEI Investments increased its Enanta Pharmaceuticals (ENTA) stake by 10% in Q1 2026, buying an estimated $138K and bringing the position to 109,077 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2194.

SEI Investments first reported a position in ENTA in Q4 2014 and has held it in 32 quarters since. The position peaked at $2.06M in Q4 2021. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

SEI Investments held 109,077 shares of Enanta Pharmaceuticals worth $1.38M as of Q1 2026.
SEI Investments bought 10,295 Enanta Pharmaceuticals shares in Q1 2026, an estimated $138K.
Enanta Pharmaceuticals made up ﹤0.01% of SEI Investments's portfolio in Q1 2026, its #2194 holding.
SEI Investments first reported a position in Enanta Pharmaceuticals in Q4 2014 and has held it in 32 quarters since.
SEI Investments's Enanta Pharmaceuticals position peaked at $2.06M in Q4 2021.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.